WHO Pharmaceuticals Newsletter 2004, No. 01
(2004; 17 pages) Voir le document au format PDF
Table des matières
Ouvrir ce répertoire et afficher son contenuREGULATORY MATTERS
Fermer ce répertoireSAFETY OF MEDICINES
Afficher le documentANTIEPILEPTICS - ADR update from Australia
Afficher le documentBOTULINUM TOXIN TYPE A - Place in therapy not clearly defined
Afficher le documentCELECOXIB/ROFECOXIB - Acute temporary visual impairment
Afficher le documentDACLIZUMAB - Increased mortality in cardiac transplant patients
Afficher le documentFLUTICASONE - Update on adrenal insufficiency reports
Afficher le documentINTERFERON BETA - Safety information about risk of liver injury
Afficher le documentMETHADONE - Risk of QT prolongation
Afficher le documentMETHOTREXATE - Update on pulmonary effects
Afficher le documentMIRTAZAPINE - ADR update from Australia
Afficher le documentMORPHINE - Accidental overdose of concentrated oral solutions
Afficher le documentNONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) - Postpartum administration may cause hypertension
Afficher le documentPERGOLIDE - Danger of falling asleep during daily activities
Afficher le documentPYRAZINAMIDE & RIFAMPICIN - Serious liver injury with combined use in latent tuberculosis
Afficher le documentSIBUTRAMINE - ADR update
Afficher le documentTOPIRAMATE - Warning about metabolic acidosis
Afficher le documentWARFARIN - Interaction with cranberry juice
Ouvrir ce répertoire et afficher son contenuDRUGS OF CURRENT INTEREST
Ouvrir ce répertoire et afficher son contenuFEATURE
 

WARFARIN - Interaction with cranberry juice

UK. The Committee on Safety of Medicines (CSM) has drawn attention to a possible interaction between warfarin and cranberry juice. Since 1999 the CSM has received five reports of a possible interaction between warfarin and cranberry juice leading to changes in the International Normalized Ratio (INR) values. One case was fatal and involved a man whose INR increased to more than 50 six weeks after he started drinking cranberry juice; he died of gastrointestinal and pericardial haemorrhage. Two other patients experienced increased INRs when taking cranberry juice; one patient stabilised following a reduction in warfarin dosage and the other's INR normalised after cranberry juice was stopped. A fourth patient experienced an unstable INR, and a decreased INR was reported in another patient. The CSM notes that the interaction is biologically plausible through inhibition of cytochrome P450 by flavonoids in cranberry juice and suggest that, until the possible interaction is investigated further, it would be prudent for patients taking warfarin to limit or avoid drinking cranberry juice.

Reference:
Current Problems in Pharmacovigilance, September 2003. Available from URL: http://www.mca.gov.uk

 

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013